Teva Pharmaceutical's Transformation: A Cautionary Tale for Investors Teva Pharmaceutical Industries Limited is preparing to ditch its American Depository Shares (ADSs) in favor of a direct listing on the NYSE, sparking investor interest.
This move has been hailed as a sign of the company's commitment to growth and innovation, but beneath the surface lies a more complex story.
Teva's transformation from a generics focused firm to a branded drug powerhouse has been remarkable.